leisure time -WSS

leisure time

author：fashion 2025-10-02 19:19:43 - browse：747

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The system is set up to fail children with medical complexity

focus

WSS

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

New report analyzes digital physical therapy solutions' effectiveness

Pharma companies must ensure equitable access to obesity drugs

Teladoc has a new CEO, but challenges remain the same

Latigo launches with $135 million for Vertex

Curing rare childhood diseases will falter unless Congress steps up

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Heart attack and stroke risk calculators need revising

5 takeaways from STAT's examination of Zynex Medical

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How faith leaders like me can help address America's obesity epidemic

In Memoriam: Notable people who died in 2023

Having children helps parents live longer, especially after age 80

Peter Hotez and the public health issue of online harassment

Here’s what’s in the FDA plan to include pregnant women in clinical trials

hotspot

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Why don't Americans have at

5 takeaways from STAT's examination of Zynex Medical

The system is set up to fail children with medical complexity

AMAs digital advisors table RPM coding reform proposal, again

knowledge

leisure time

focus

entertainment